ClinicalTrials.gg
CompletedNCT01024660Updated Feb 8, 2011

The Effect of Cognitive Function as Measured by Repeated Cognitive Measures After 12 Weeks Treatment With Donepezil

An Early Phase 1 interventional study of Donepezil and Donepezil in Alzheimer's Disease, sponsored by AstraZeneca. Completed at 18 sites in 4 countries. Open to participants aged 55 Years to 85 Years. Per ClinicalTrials.gov, last updated 2011-02-08.

Sponsored by AstraZeneca · Early Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
155
Allocation
Randomized
Ages
55 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 60 studies testing donepezil in Alzheimer Disease — 2 open to participants now, 2 under way, 1 of them phase 3. Donepezil · Alzheimer Disease.

Planned enrollment
19th of 58
155 · median 79
Started
2009
with 1 other
Phase 1
20 of 60
1 open now
Registered
29th of 60
by date
Lead sponsor
3 of 60
AstraZeneca

Among the 60 studies testing donepezil in Alzheimer Disease, this one is the 19th largest by planned enrollment of the 58 interventional ones that give a count, is one of 2 that started in 2009, is one of 20 in phase 1, and was the 29th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 928 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

2 of the 60 studies testing donepezil in Alzheimer Disease are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About donepezil

Donepezil: first FDA approval 1996 (ARICEPT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 55 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing donepezil in Alzheimer Disease, or all of them as a file.
02

Study summary

The purpose of this study is to determine if there is improvement or measurable change in cognition after only one month of treatment with donepezil when using a computerized test battery. The results at one month will be compared with the results at 3 months to evaluate this.

03

Conditions studied

  • Alzheimer's Disease

Browse trials for

Keywords

  • Patients with Mild to Moderate Alzheimer's Disease
04

Who can participate

Ages eligible
55 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of probable AD according to NINCDS-ADRDA criteria.
  • The patient should live with an appropriate caregiver at home, or in a community dwelling. A caregiver should be capable of accompanying the patient to clinic visits or attending study visits in the patient's home.
  • Patient and caregiver should understand, speak, and read local language.

Exclusion criteria

Exclusion Criteria:

  • Significant neurological disease or dementia other than AD, e.g., mixed dementia, frontotemporal dementia, and Parkinson's Disease.
  • Females of child bearing potential
  • Impaired vision or hearing
05

Study design

Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
155 participants (estimated)

Study arms

  • Active comparator
    1

    5 mg Donepezil (first 14 days), 10 mg Donepezil (next 70 days)

    Drug: Donepezil

  • Placebo comparator
    2

    Drug: Placebo to match Aricept

Interventions

  • 5 mg capsule, orally, once daily, first 14 days of treatment

    Also known as: Aricept

  • 10 mg, orally, once daily, for remaining 70 days of treatment

    Also known as: Aricept

  • DrugPlacebo to match Aricept

    Placebo capsule, orally, 84 days of treatment

06

What researchers measure

Primary outcomes

  1. CogState Computerized Neurological Test Battery

    Time frame: Tl. of 25 times: 10 times between Days 3-14, 5 times between Days 36-42, 5 times between Days 64-70, four times between Days 92-97, 1 time on Day 98

Secondary outcomes

  1. Neuropsychological Test Battery (NTB)

    Time frame: Tl. of 5 times: Once between Days 1-2, Once anytime between Days 3-14, Once anytime between Days 36-42, Once anytime between Days 64-70, Once between Days 92-97

  2. Alzheimer Disease Assessment Scale-Cognitive (ADAS-Cog)

    Time frame: Tl. of 5 times: Once between Days 1-2, Once anytime between Days 3-14, Once anytime between Days 36-42, Once anytime between Days 64-70, Once between Days 92-97

  3. Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC)

    Time frame: Tl. of 4 times: Once anytime between Days 3-14, Once anytime between Days 36-42, Once anytime between Days 64-70, Once between Days 92-97

07

Study locations

18 sites
  • Research Site
    Ottawa, Ontario, Canada
  • Research Site
    Gatineau, Quebec, Canada
  • Research Site
    Montreal, Quebec, Canada
  • Reearch Site
    Quebec, Canada
  • Research Site
    Quebec, Canada
  • Research Site
    Callao, Lima, Peru
  • Research Site
    Callao, Peru
  • Research Site
    Lima, Peru
  • Research Site
    Chojnice, Poland
  • Research Site
    Gdansk, Poland
  • Research Site
    Kalisz, Poland
  • Research Site
    Pila, Poland
  • Research Site
    Poznan, Poland
  • Research Site
    Scinawa, Poland
  • Research Site
    Sopot, Poland
  • Research Site
    Warszawa, Poland
  • Research Site
    Cape Town, Western Cape, South Africa
  • Research Site
    Roodepoort, South Africa
08

References and documents

Publications

  • Karin A, Hannesdottir K, Jaeger J, Annas P, Segerdahl M, Karlsson P, Sjogren N, von Rosen T, Miller F. Psychometric evaluation of ADAS-Cog and NTB for measuring drug response. Acta Neurol Scand. 2014 Feb;129(2):114-22. doi: 10.1111/ane.12153. Epub 2013 Jun 13. PubMed 23763450 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2009, a primary completion of Jan 2011 and a completion of Jan 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2009
First posted
Dec 3, 2009
Start
Dec 2009
Primary completionActual
Jan 2011
CompletionActual
Jan 2011
Last update
Feb 8, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01024660
Lead sponsor
AstraZeneca
First posted
Dec 3, 2009
Start date
Dec 2009
Primary completion
Jan 2011
Completion
Jan 2011
Last update
Feb 8, 2011

Study contacts

Malene Jensen
study director · Study Delievery Director, AstraZeneca

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Donepezil

Start the discussion